









### **ABSTRACT**

### **Purpose**

The study aimed to compare corneal topographic and specular microscopic parameters before and after vaccination with activated (Pfizer -BioNTech (BNT162b2)) SARS-CoV-2 mRNA vaccine.

#### Methods

128 eyes of 64 patients were evaluated in this prospective study. The time interval between pre and post-vaccination examinations was nearly two and a half months (75.6 ± 4.5 days). The topographic evaluation was made with Sirius corneal topography (Sirius, CSO Inc, Florence, Italy) and specular microscopy was made with Tomey EM-4000 specular microscopy (Tomey GmbH, Japan). All patients underwent detailed ophthalmologic examination including best-corrected visual acuity assessment (BCVA), measurement of intraocular pressure (IOP), anterior segment evaluation with biomicroscopy, and dilated fundus examination.

## Results

The significant change in the topographic evaluation was the post-vaccine (542.0 (534.25–548.0)) increase in central corneal thickness compared to pre-vaccine values (528.0 (520.25–537.75) (p = 0.001). The endothelial cell density (ECD) was 2597 (2550.0–2646.50) before vaccination and 2378.0 (2299.0–2419.0) at least two months after vaccination (p < 0.001). The median mean coefficient of variation (CV) value was 39.0(38.0–42.0) before vaccination measurements and 42 (40–44) after vaccination measurements (p < 0.001). The mean hexagonality was 50.0 (48.25–52.0) before vaccination and 48(46–49) after vaccination (p < 0.001). The median central corneal thickness (CCT) value was 533(526–538) before vaccination and 548 (543.50–556) after vaccination (p < 0.001).

#### Conclusion

Changes in corneal endothelium occur in the short term after two-doses of the Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine. Hence the endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft.

#### **KEYWORDS:**

Cornea endothelial	Covid-19	specular microscopy	topography	vaccine	
Previous	us article	<b>View</b> la	test articles		Next article >

### Disclosure statement

No potential conflict of interest was reported by the author(s).

# Data availability statement

Data supporting the findings of this study are available from the corresponding author [FS] upon reasonable request.

# **Additional information**

# **Funding**

The author(s) reported there is no funding associated with the work featured in this article.





Related research 1



Recommended articles

Cited by

Information for

Open access

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

## Keep up to date

Register to receive personalised research and resources by email















conditions Accessibility



Copyright © 2025 Informa UK Limited Privacy policy Cookies Terms &

Taylor & Francis Group an informa business

Registered in England & Wales No. 01072954 5 Howick Place | London | SW1P 1WG